An AI scribe for doctors just became a near-unicorn in a country that's not exactly known for healthcare software giants.
The Summary
- Heidi, a Melbourne-based AI healthcare startup, raised $100M at a $900M valuation — nearly unicorn status for clinical workflow automation
- The company builds AI tools that handle medical documentation, research synthesis, and consultation efficiency for doctors
- Signals a major shift: healthcare AI is moving from diagnostic moonshots to unglamorous workflow problems that actually save physicians hours every day
The Signal
Heidi's valuation tells you where smart money thinks healthcare AI actually works. Not in replacing radiologists or predicting cancer from your iPhone camera. In the tedious documentation work that burns out doctors faster than the patients do.
The company targets three specific pain points: streamlining research so doctors don't spend evenings reading journals, automating clinical workflows so documentation doesn't eat half the day, and making consultations more efficient so the human part of medicine gets more time. That's the entire pitch. No magical diagnosis. No robot surgeon. Just give doctors their time back.
"Healthcare AI valuations are finally rewarding companies that solve workflow problems, not science fiction problems."
The $900M number matters because it validates a specific bet. Healthcare has two kinds of AI companies. The first kind promises to revolutionize diagnosis and compete with specialists. They get TED talks and FDA approval battles. The second kind promises to make the existing system less soul-crushing for the people inside it. Heidi is the second kind, and that second kind just got near-unicorn pricing.
Melbourne as the launch point is non-obvious. Australia's healthcare system is smaller scale than the US but complex enough to stress-test AI tools. Universal coverage means every workflow improvement has immediate ROI visibility. And Australian doctors are early adopters of clinical software because the alternative is drowning in the same documentation burden that's killing their US counterparts.
The Implication
Watch for Heidi's US expansion plans. The American healthcare market is where workflow AI either scales to billions or dies in pilot purgatory. If they crack hospital system procurement, this becomes a multi-billion dollar story. If they don't, the $900M valuation looks expensive for a productivity tool.
The broader signal: we're entering the phase where healthcare AI wins by making doctors more human, not more obsolete. The companies building augmentation tools for clinicians are getting funded like infrastructure, not like moonshots. That's the adult phase of healthcare AI.